The US Food and Drug Administration (FDA) has provided clearance for RapidAI’s five new artificial intelligence (AI) modules. The newly cleared modules—Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic—are designed to move beyond simple triage, helping physicians characterize, quantify, and track diseases over time.
The clearances significantly expand the capabilities of the company’s Rapid Enterprise Platform, advancing its goal of providing deep clinical intelligence for hospitals.
Each new module addresses a specific clinical need:
- Rapid DeltaFuse automatically aligns serial head CT scans to visualize subtle changes in the brain, reportedly reducing radiologist comparison time by over 36%.
- Rapid LMVO extends the company’s stroke imaging suite by enabling complete brain vessel coverage on CT angiography.
- Rapid MLS detects and quantifies midline shift in the brain, a key indicator of injury, with a high degree of accuracy.
- Rapid OH identifies suspected obstructive hydrocephalus in under a minute, expediting triage. It also qualifies for a CMS New Technology Add-on Payment.
- Rapid Aortic provides consistent, guideline-based measurements of the aorta from any CT scan, aiding in surgical planning and long-term surveillance.
Reducing Cognitive Burden for Clinicians
A central tenet of RapidAI’s approach is reducing the cognitive burden on radiologists. By automating complex measurements and visualizations, the tools allow clinicians to focus more on clinical judgment and less on manual data manipulation.
“RapidAI algorithms help set new standards by enabling radiologists to practice at the top of their license, reducing cognitive burden, and improving clinical decision-making,” said Karim Karti, CEO of RapidAI.
The new modules are fully integrated into the Rapid Edge Cloud platform and the company’s radiology solution, Rapid Navigator Pro. According to the company, this ensures a seamless experience across hospital systems like PACS and EHR, allowing radiologists to access AI insights without disrupting their clinical workflow.
RapidAI boasts that its platform is now used by more than 2,500 hospitals in over 100 countries, backed by more than 700 clinical studies.
Recent Funding Activity
The healthcare sector has seen a flurry of activity in AI-related funding in recent months. Recently, US-based Sorcero announced the closing of a $42.5 million Series B funding round for its artificial intelligence (AI) platform. University of California, Berkeley (UC Berkley) spin-off Voio, a frontier AI lab dedicated to healthcare, emerged from stealth with $8.6 million in seed funding.
In October, another Israeli health technology startup, CustoMED, raised $6 million in seed funding to advance its AI-powered 3D printing applications in orthopedic surgery. In July, health tech startup Respiree raised $11.6 million in a Series A funding round to scale its artificial intelligence (AI) based patient monitoring platform and expand its global footprint.
